1. Home
  2. BRBS vs CBIO Comparison

BRBS vs CBIO Comparison

Compare BRBS & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BRBS
  • CBIO
  • Stock Information
  • Founded
  • BRBS 1893
  • CBIO 2003
  • Country
  • BRBS United States
  • CBIO United States
  • Employees
  • BRBS N/A
  • CBIO N/A
  • Industry
  • BRBS Commercial Banks
  • CBIO
  • Sector
  • BRBS Finance
  • CBIO
  • Exchange
  • BRBS Nasdaq
  • CBIO Nasdaq
  • Market Cap
  • BRBS 326.4M
  • CBIO 308.0M
  • IPO Year
  • BRBS N/A
  • CBIO N/A
  • Fundamental
  • Price
  • BRBS $4.02
  • CBIO $14.29
  • Analyst Decision
  • BRBS
  • CBIO Strong Buy
  • Analyst Count
  • BRBS 0
  • CBIO 5
  • Target Price
  • BRBS N/A
  • CBIO $25.60
  • AVG Volume (30 Days)
  • BRBS 444.7K
  • CBIO 98.3K
  • Earning Date
  • BRBS 10-28-2025
  • CBIO 07-31-2025
  • Dividend Yield
  • BRBS N/A
  • CBIO N/A
  • EPS Growth
  • BRBS N/A
  • CBIO N/A
  • EPS
  • BRBS N/A
  • CBIO N/A
  • Revenue
  • BRBS $96,787,000.00
  • CBIO N/A
  • Revenue This Year
  • BRBS N/A
  • CBIO N/A
  • Revenue Next Year
  • BRBS N/A
  • CBIO N/A
  • P/E Ratio
  • BRBS N/A
  • CBIO N/A
  • Revenue Growth
  • BRBS 10.13
  • CBIO N/A
  • 52 Week Low
  • BRBS $2.66
  • CBIO $10.83
  • 52 Week High
  • BRBS $4.14
  • CBIO $21.40
  • Technical
  • Relative Strength Index (RSI)
  • BRBS 63.43
  • CBIO 52.92
  • Support Level
  • BRBS $3.63
  • CBIO $13.50
  • Resistance Level
  • BRBS $4.14
  • CBIO $16.00
  • Average True Range (ATR)
  • BRBS 0.12
  • CBIO 0.79
  • MACD
  • BRBS 0.03
  • CBIO 0.16
  • Stochastic Oscillator
  • BRBS 75.49
  • CBIO 39.68

About BRBS Blue Ridge Bankshares Inc.

Blue Ridge Bankshares Inc is a United States-based company engaged in offering commercial and consumer banking and financial services through its wholly-owned bank subsidiary, Blue Ridge Bank, National Association, and its non-bank financial services affiliates. The bank offers services such as checking accounts, savings accounts, money market accounts, cash management accounts, commercial and industrial loans, residential mortgages, commercial mortgages, home equity loans, consumer installment loans, investment accounts, insurance and others. It has three reportable business segments: commercial banking, mortgage banking, and holding company activities.

About CBIO Crescent Biopharma Inc. Common Stock

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

Share on Social Networks: